Literature DB >> 18258414

IFN-alpha-induced motor slowing is associated with increased depression and fatigue in patients with chronic hepatitis C.

Matthias Majer1, Leonie A M Welberg, Lucile Capuron, Giuseppe Pagnoni, Charles L Raison, Andrew H Miller.   

Abstract

Interferon (IFN)-alpha has been used to investigate pathways by which innate immune cytokines influence the brain and behaviour. Previous studies suggest that altered basal ganglia function may contribute to IFN-alpha-induced neuropsychological and behavioural changes. To further examine IFN-alpha effects on neuropsychological functions related to basal ganglia (as well as other brain regions), and explore the relationship between altered neuropsychological function and IFN-alpha-induced depression and fatigue, a selected subset of the Cambridge Neuropsychological Test Automated Battery was administered to 32 hepatitis C patients at baseline (Visit 1) and following approximately 12 weeks (Visit 2) of either no treatment (n=12) or treatment with IFN-alpha plus ribavirin (n=20). Symptoms of depression and fatigue were assessed using the Montgomery-Asberg Depression Rating Scale and the Multidimensional Fatigue Inventory. Compared to control subjects, patients treated with IFN-alpha/ribavirin exhibited significant decreases in motor speed as measured in the simple and five-choice movement segments of the CANTAB reaction time task and slower response times in the rapid visual information processing task, a task of sustained attention. Decreased motor speed on the five-choice movement segments of the reaction time task was in turn correlated with increased symptoms of depression and fatigue (R=0.47, p<0.05 and R=0.48, p<0.05, respectively). IFN-alpha/ribavirin treatment had no effects on executive function, decision time in the reaction time task, or target detection accuracy in the sustained attention task. Motor slowing and its correlation with psychiatric symptoms suggest that altered basal ganglia function may contribute to the pathogenesis of IFN-alpha-induced behavioural changes.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18258414      PMCID: PMC2497339          DOI: 10.1016/j.bbi.2007.12.009

Source DB:  PubMed          Journal:  Brain Behav Immun        ISSN: 0889-1591            Impact factor:   7.217


  88 in total

Review 1.  Basal ganglia and cerebellar loops: motor and cognitive circuits.

Authors:  F A Middleton; P L Strick
Journal:  Brain Res Brain Res Rev       Date:  2000-03

2.  Intravenous administration of levodopa ameliorated a refractory akathisia case induced by interferon-alpha.

Authors:  M Sunami; T Nishikawa; A Yorogi; M Shimoda
Journal:  Clin Neuropharmacol       Date:  2000 Jan-Feb       Impact factor: 1.592

3.  Effects of interferon-alpha on rhesus monkeys: a nonhuman primate model of cytokine-induced depression.

Authors:  Jennifer C Felger; Oyetunde Alagbe; Fang Hu; Deborah Mook; Amanda A Freeman; Mar M Sanchez; Ned H Kalin; Emiliangelo Ratti; Charles B Nemeroff; Andrew H Miller
Journal:  Biol Psychiatry       Date:  2007-08-02       Impact factor: 13.382

Review 4.  The role of dopamine in the pathophysiology of depression.

Authors:  Boadie W Dunlop; Charles B Nemeroff
Journal:  Arch Gen Psychiatry       Date:  2007-03

5.  Kynurenic acid leads, dopamine follows: a new case of volume transmission in the brain?

Authors:  H-Q Wu; A Rassoulpour; R Schwarcz
Journal:  J Neural Transm (Vienna)       Date:  2006-08-24       Impact factor: 3.575

6.  Dopaminergic abnormalities in amygdaloid nuclei in major depression: a postmortem study.

Authors:  Violetta Klimek; Jane E Schenck; Hui Han; Craig A Stockmeier; Gregory A Ordway
Journal:  Biol Psychiatry       Date:  2002-10-01       Impact factor: 13.382

7.  Basal ganglia hypermetabolism and symptoms of fatigue during interferon-alpha therapy.

Authors:  Lucile Capuron; Giuseppe Pagnoni; Marina F Demetrashvili; David H Lawson; Fiona B Fornwalt; Bobbi Woolwine; Gregory S Berns; Charles B Nemeroff; Andrew H Miller
Journal:  Neuropsychopharmacology       Date:  2007-02-28       Impact factor: 7.853

Review 8.  Nucleus accumbens dopamine and the regulation of effort in food-seeking behavior: implications for studies of natural motivation, psychiatry, and drug abuse.

Authors:  J D Salamone; M Correa; S Mingote; S M Weber
Journal:  J Pharmacol Exp Ther       Date:  2003-04       Impact factor: 4.030

9.  Depression following pegylated interferon-alpha: characteristics and vulnerability.

Authors:  Francis E Lotrich; Mordechai Rabinovitz; Patricia Gironda; Bruce G Pollock
Journal:  J Psychosom Res       Date:  2007-08       Impact factor: 3.006

10.  Interferon-induced fatigue in patients with melanoma: a pilot study of exercise and methylphenidate.

Authors:  Anna L Schwartz; John A Thompson; Nehal Masood
Journal:  Oncol Nurs Forum       Date:  2002-08       Impact factor: 2.172

View more
  63 in total

1.  Chronic interferon-alpha administration disrupts sleep continuity and depth in patients with hepatitis C: association with fatigue, motor slowing, and increased evening cortisol.

Authors:  Charles L Raison; David B Rye; Bobbi J Woolwine; Gerald J Vogt; Breanne M Bautista; James R Spivey; Andrew H Miller
Journal:  Biol Psychiatry       Date:  2010-05-26       Impact factor: 13.382

2.  Differential actions of adenosine A1 and A2A antagonists on the effort-related effects of dopamine D2 antagonism.

Authors:  John D Salamone; Andrew M Farrar; Laura Font; Vatsal Patel; Devra E Schlar; Eric J Nunes; Lyndsey E Collins; Thomas N Sager
Journal:  Behav Brain Res       Date:  2009-03-03       Impact factor: 3.332

3.  The adenosine A2A antagonist MSX-3 reverses the effort-related effects of dopamine blockade: differential interaction with D1 and D2 family antagonists.

Authors:  Lila T Worden; Mona Shahriari; Andrew M Farrar; Kelly S Sink; Jörg Hockemeyer; Christa E Müller; John D Salamone
Journal:  Psychopharmacology (Berl)       Date:  2008-12-02       Impact factor: 4.530

4.  Inflammation-induced motivational changes: Perspective gained by evaluating positive and negative valence systems.

Authors:  Elisabeth G Vichaya; Robert Dantzer
Journal:  Curr Opin Behav Sci       Date:  2018-02-10

5.  Norman Cousins Lecture. Mechanisms of cytokine-induced behavioral changes: psychoneuroimmunology at the translational interface.

Authors:  Andrew H Miller
Journal:  Brain Behav Immun       Date:  2008-09-03       Impact factor: 7.217

6.  Chronic interferon-α decreases dopamine 2 receptor binding and striatal dopamine release in association with anhedonia-like behavior in nonhuman primates.

Authors:  Jennifer C Felger; Jiyoung Mun; Heather L Kimmel; Jonathon A Nye; Daniel F Drake; Carla R Hernandez; Amanda A Freeman; David B Rye; Mark M Goodman; Leonard L Howell; Andrew H Miller
Journal:  Neuropsychopharmacology       Date:  2013-05-09       Impact factor: 7.853

7.  Activation of central nervous system inflammatory pathways by interferon-alpha: relationship to monoamines and depression.

Authors:  Charles L Raison; Andrey S Borisov; Matthias Majer; Daniel F Drake; Giuseppe Pagnoni; Bobbi J Woolwine; Gerald J Vogt; Breanne Massung; Andrew H Miller
Journal:  Biol Psychiatry       Date:  2008-09-18       Impact factor: 13.382

Review 8.  Immune system to brain signaling: neuropsychopharmacological implications.

Authors:  Lucile Capuron; Andrew H Miller
Journal:  Pharmacol Ther       Date:  2011-02-17       Impact factor: 12.310

Review 9.  Mechanisms by which sleep disturbance contributes to osteoarthritis pain: a conceptual model.

Authors:  Michael T Smith; Phillip J Quartana; Renata M Okonkwo; Adeel Nasir
Journal:  Curr Pain Headache Rep       Date:  2009-12

10.  CSF concentrations of brain tryptophan and kynurenines during immune stimulation with IFN-alpha: relationship to CNS immune responses and depression.

Authors:  C L Raison; R Dantzer; K W Kelley; M A Lawson; B J Woolwine; G Vogt; J R Spivey; K Saito; A H Miller
Journal:  Mol Psychiatry       Date:  2009-11-17       Impact factor: 15.992

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.